{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:03:40Z","timestamp":1782299020367,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12325-021-01713-x","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T09:03:30Z","timestamp":1618218210000},"page":"2586-2598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5368-7518","authenticated-orcid":false,"given":"Nabeel","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Pernes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinmay","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manthankumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"issue":"12","key":"1713_CR1","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/apt.14688","volume":"47","author":"P Sehgal","year":"2018","unstructured":"Sehgal P, Colombel JF, Aboubakr A, Narula N. Systematic review: safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther. 2018;47(12):1597\u2013609.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1713_CR2","doi-asserted-by":"publisher","first-page":"e0158017","DOI":"10.1371\/journal.pone.0158017","volume":"11","author":"AK Waljee","year":"2016","unstructured":"Waljee AK, Wiitala WL, Govani S, et al. Corticosteroid use and complications in a US inflammatory bowel disease cohort [published correction appears in PLoS One. 2018 May 9;13(5):e0197341]. PLoS One. 2016;11(6):e0158017. https:\/\/doi.org\/10.1371\/journal.pone.0158017.","journal-title":"PLoS One"},{"key":"1713_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","volume":"11","author":"M Harbord","year":"2017","unstructured":"Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769\u201384.","journal-title":"J Crohns Colitis"},{"key":"1713_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384\u2013413.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"1713_CR5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/1744666X.2019.1646127","volume":"15","author":"A Holmer","year":"2019","unstructured":"Holmer A, Singh S. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases. Expert Rev Clin Immunol. 2019;15(9):969\u201379. https:\/\/doi.org\/10.1080\/1744666X.2019.1646127.","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"1713_CR6","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","volume":"17","author":"NZ Borren","year":"2019","unstructured":"Borren NZ, Ananthakrishnan AN. Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(9):1736-1743.e4. https:\/\/doi.org\/10.1016\/j.cgh.2018.12.032.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1713_CR7","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S0016-5085(98)70421-4","volume":"114","author":"EV Loftus Jr","year":"1998","unstructured":"Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn\u2019s disease in Olmsted County, Minnesota, 1940\u20131993: incidence, prevalence, and survival. Gastroenterology. 1998;114:1161\u20138.","journal-title":"Gastroenterology"},{"key":"1713_CR8","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1136\/gut.46.3.336","volume":"46","author":"EV Loftus Jr","year":"2000","unstructured":"Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940\u20131993: incidence, prevalence, and survival. Gut. 2000;46:336\u201343.","journal-title":"Gut"},{"issue":"3","key":"1713_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/gutjnl-2012-303864","volume":"63","author":"C Charpentier","year":"2014","unstructured":"Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63(3):423\u201332.","journal-title":"Gut"},{"key":"1713_CR10","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1002\/ibd.22940","volume":"18","author":"ER Fedyk","year":"2012","unstructured":"Fedyk ER, Wyant T, Yang LL, et al. Exclusive antagonism of the \u03b14\u03b27 integrin by VDZ confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis. 2012;18:2107\u201319.","journal-title":"Inflamm Bowel Dis"},{"key":"1713_CR11","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.4049\/jimmunol.1202490","volume":"190","author":"KG Haanstra","year":"2013","unstructured":"Haanstra KG, Hofman SO, Lopes Estevao DM, et al. Antagonizing the \u03b14\u03b21 integrin, but not \u03b14\u03b27, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunol. 2013;190:1961\u201373.","journal-title":"J Immunol"},{"key":"1713_CR12","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1124\/jpet.109.153973","volume":"330","author":"D Soler","year":"2009","unstructured":"Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of VDZ, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864\u201375.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1713_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/apt.15538","volume":"51","author":"T Card","year":"2020","unstructured":"Card T, Ungaro R, Bhayat F, Blake A, Hantsbarger G, Travis S. Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. Aliment Pharmacol Ther. 2020;51(1):149\u201357.","journal-title":"Aliment Pharmacol Ther"},{"issue":"13","key":"1713_CR14","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215\u201326.","journal-title":"N Engl J Med"},{"issue":"2","key":"1713_CR15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/j.1875-9114.1990.tb02553.x","volume":"10","author":"SL Dahl","year":"1990","unstructured":"Dahl SL, Samuelson CO, Williams HJ, Ward JR, Karg M. Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trials. Pharmacotherapy. 1990;10(2):79\u201384.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"1713_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6\u201314. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.02007.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1713_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/ajg.2017.479","volume":"113","author":"JD Lewis","year":"2018","unstructured":"Lewis JD, Scott FI, Brensinger CM, et al. Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-\u03b1-directed therapy for inflammatory bowel disease. Am J Gastroenterol. 2018;113(3):405.","journal-title":"Am J Gastroenterol"},{"key":"1713_CR18","unstructured":"US Department of Veterans Affairs. https:\/\/www.va.gov\/health\/#:~:text=The%20Veterans%20Health%20Administration%20is%20America's%20largest%20integrated%20health%20care,million%20enrolled%20Veterans%20each%20year."},{"key":"1713_CR19","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/jgs.13702","volume":"63","author":"American Geriatrics Society 2015 Updated Beers Criteria Update Expert Panel","year":"2015","unstructured":"American Geriatrics Society 2015 Updated Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227\u201346.","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"1713_CR20","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.cgh.2017.12.052","volume":"16","author":"N Khan","year":"2018","unstructured":"Khan N, Patel D, Trivedi C, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol. 2018;16(12):1919\u201327.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1713_CR21","unstructured":"He W, Goodkind D, Kowal PR. An aging world: 2015; International Population Reports; United States Census Bureau; Issued March 2016."},{"issue":"4","key":"1713_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(16)30077-2","volume":"1","author":"GG Kaplan","year":"2016","unstructured":"Kaplan GG, Ng SC. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol Hepatol. 2016;1(4):307\u201316.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"1713_CR23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720\u20137.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1713_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","volume":"9","author":"M Cottone","year":"2011","unstructured":"Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30\u20135.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1713_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ibd.23026","volume":"19","author":"A Desai","year":"2013","unstructured":"Desai A, Zator ZA, de Silva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:309\u201315.","journal-title":"Inflamm Bowel Dis"},{"key":"1713_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/apt.13294","volume":"42","author":"T Lobaton","year":"2015","unstructured":"Lobaton T, Ferrante M, Rutgeerts P, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42:441\u201351.","journal-title":"Aliment Pharmacol Ther"},{"key":"1713_CR27","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s12325-016-0467-6","volume":"34","author":"V Yajnik","year":"2017","unstructured":"Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab in ulcerative colitis and Crohn\u2019s disease patients stratified by age. Adv Ther. 2017;34:542\u201359.","journal-title":"Adv Ther"},{"issue":"7","key":"1713_CR28","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/apt.15177","volume":"49","author":"T Adar","year":"2019","unstructured":"Adar T, Faleck D, Sasidharan S, et al. Comparative safety and effectiveness of tumor necrosis factor \u03b1 antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019;49(7):873\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"1713_CR29","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.dld.2018.07.007","volume":"50","author":"MV Lenti","year":"2018","unstructured":"Lenti MV, Levison S, Eliadou E, et al. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: the Cross Pennine study. Dig Liver Dis. 2018;50(12):1299\u2013304.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"1713_CR30","first-page":"170","volume":"33","author":"H Ibraheim","year":"2020","unstructured":"Ibraheim H, Samaan MA, Srinivasan A, et al. Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. Ann Gastroenterol. 2020;33(2):170.","journal-title":"Ann Gastroenterol"},{"issue":"4","key":"1713_CR31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/gastro\/goz041","volume":"8","author":"P Shashi","year":"2020","unstructured":"Shashi P, Gopalakrishnan D, Parikh MP, Shen B, Kochhar G. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case\u2013control study. Gastroenterol Rep. 2020;8(4):306\u201311.","journal-title":"Gastroenterol Rep"},{"issue":"2","key":"1713_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/ecco-jcc\/jjz137","volume":"14","author":"RD Cohen","year":"2020","unstructured":"Cohen RD, Bhayat F, Blake A, Travis S. The safety profile of vedolizumab in ulcerative colitis and Crohn\u2019s disease: 4 years of global post-marketing data. J Crohns Colitis. 2020;14(2):192\u2013204.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"1713_CR33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn\u2019s disease in adults. Offic J Am College Gastroenterol ACG. 2018;113(4):481\u2013517.","journal-title":"Offic J Am College Gastroenterol ACG"},{"key":"1713_CR34","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710.","journal-title":"N Engl J Med"},{"issue":"8","key":"1713_CR35","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1215739.","journal-title":"N Engl J Med"},{"issue":"4","key":"1713_CR36","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ecco-jcc\/jjw176","volume":"11","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Loftus EV Jr, Colombel JF, et al. Long-term efficacy of vedolizumab for Crohn\u2019s disease. J Crohns Colitis. 2017;11(4):412\u201324. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw176.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"1713_CR37","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut. 2017;66(5):839\u201351.","journal-title":"Gut"},{"issue":"11","key":"1713_CR38","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40266-017-0498-y","volume":"34","author":"N Khan","year":"2017","unstructured":"Khan N, Vallarino C, Lissoos T, Darr U, Luo M. Risk of malignancy in a nationwide cohort of elderly inflammatory bowel disease patients. Drugs Aging. 2017;34(11):859\u201368.","journal-title":"Drugs Aging"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01713-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01713-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01713-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T23:51:21Z","timestamp":1698882681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01713-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1713"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01713-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,12]]},"assertion":[{"value":"18 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}